Ovejero-Benito María C, Prieto-Pérez Rocío, Llamas-Velasco Mar, Muñoz-Aceituno Ester, Reolid Alejandra, Saiz-Rodríguez Miriam, Belmonte Carmen, Román Manuel, Ochoa Dolores, Talegón María, Cabaleiro Teresa, Daudén Esteban, Abad-Santos Francisco
Department of Clinical Pharmacology, Hospital Universitario de la Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria la Princesa (IIS-IP), E28006, Madrid, Spain.
Department of Dermatology, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria la Princesa (IIS-IP), E28006, Madrid, Spain.
Pharmacogenomics. 2018 Jan;19(1):7-16. doi: 10.2217/pgs-2017-0143. Epub 2017 Dec 1.
This study evaluated the influence of pharmacogenetics in psoriatic patients treated with adalimumab and/or infliximab.
MATERIALS & METHODS: Prospective observational study evaluating the association of 124 polymorphisms with the response to adalimumab or infliximab (PASI75) in patients with moderate-to-severe plaque psoriasis at 3 months (n = 95) and 6 months of treatment (n = 90). Significant SNPs for univariate analysis were subjected to multivariate analysis.
Five SNPs were associated with PASI75 at 3 months: rs6661932 (IVL), rs2546890 (IL-12B), rs2145623 (NFKBIA), rs9304742 (ZNF816A) and rs645544 (SLC9A8). Furthermore, rs1061624 (TNFR1B) was associated with PASI75 at 6 months.
Nevertheless, these biomarkers should be validated in large-scale studies before implementation in clinical practice.
本研究评估了药物遗传学对接受阿达木单抗和/或英夫利昔单抗治疗的银屑病患者的影响。
前瞻性观察性研究，评估124个多态性与中重度斑块状银屑病患者在治疗3个月（n = 95）和6个月（n = 90）时对阿达木单抗或英夫利昔单抗反应（PASI75）的相关性。对单变量分析中有意义的单核苷酸多态性（SNP）进行多变量分析。
5个SNP在3个月时与PASI75相关：rs6661932（IVL）、rs2546890（IL-12B）、rs2145623（NFKBIA）、rs9304742（ZNF816A）和rs645544（SLC9A8）。此外，rs1061624（TNFR1B）在6个月时与PASI75相关。
然而，在临床实践中应用这些生物标志物之前，应在大规模研究中对其进行验证。
